{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:01:18Z","timestamp":1793674878824,"version":"4.5.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The neutrophil\/ lymphocyte ratio (NLR) and platelet\/lymphocyte ratio (PLR) have the potential to be inflammatory markers that reflect the activity of many inflammatory diseases. The aim of this study was to evaluate the NLR and PLR as potential markers of disease activity in patients with ankylosing spondylitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study involved 132 patients with ankylosing spondylitis and 81 healthy controls matched in terms of age and gender. Their sociodemographic data, disease activity scores using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), erythrocyte sedimentation rate (ESR), and white blood cell, neutrophil, lymphocyte and platelet counts were recorded. The patients with ankylosing spondylitis were further divided according to their BASDAI scores into patients with inactive disease (BASDAI &lt;\u20094) and patients with active disease (BASDAI \u22654). The correlations between the NLR, PLR and disease activity were analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was a statistically significant difference in the NLR and PLR between the active and inactive ankylosing spondylitis patients (2.31\u2009\u00b1\u20091.23 vs. 1.77\u2009\u00b1\u20090.73, <jats:italic>p<\/jats:italic>\u2009=\u20090.002), (142.04\u2009\u00b1\u200970.98 vs. 119.24\u2009\u00b1\u200932.49, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009\u00a00.001, respectively). However, there was no significant difference in both the NLR and PLR between the healthy control group and ankylosing spondylitis patients (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). In addition, the PLR was significantly higher in both the active and inactive groups compared to those in the healthy control group (142.04\u2009\u00b1\u200970.98 vs. 99.32\u2009\u00b1\u200933.97, <jats:italic>p<\/jats:italic>\u2009=\u20090.014), (119.24\u2009\u00b1\u200932.49 vs. 99.32\u2009\u00b1\u200933.97, <jats:italic>p<\/jats:italic>\u2009=\u20090.019). The BASDAI scores were positively correlated with the PLR (r\u2009=\u20090.219, <jats:italic>p<\/jats:italic>\u2009=\u20090.012) and the NLR, but they were not statistically significant with the later (r\u2009=\u20090.170, <jats:italic>p<\/jats:italic>\u2009=\u20090.051). Based on the ROC curve, the best NLR cut-off value for predicting severe disease activity in ankylosing spondylitis patients was 1.66, with a sensitivity of 61.8% and a specificity of 50.6%, whereas the best PLR cut-off value was 95.9, with a sensitivity of 70.9% and a specificity of 55.5%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The PLR may be used as a useful marker in the assessment and monitoring of disease activity in AS together with acute phase reactants such as the ESR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-020-0113-5","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T16:02:46Z","timestamp":1580400166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Neutrophil\/lymphocyte and platelet\/lymphocyte ratios as potential markers of disease activity in patients with Ankylosing spondylitis: a case-control study"],"prefix":"10.1186","volume":"60","author":[{"given":"Mohammed Hadi","family":"Al-Osami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-0146","authenticated-orcid":false,"given":"Nabaa Ihsan","family":"Awadh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Burhan","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar Ihsan","family":"Awadh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"key":"113_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379\u201390.","journal-title":"Lancet."},{"key":"113_CR2","doi-asserted-by":"publisher","unstructured":"Bascherini V, Caso F, Costa L, et al. TNF\u03b1-inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. Pharm J. 2017; 9: No 1, online | DOI: https:\/\/doi.org\/10.1211\/CP.2017.20202077","DOI":"10.1211\/CP.2017.20202077"},{"issue":"12","key":"113_CR3","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing spondylitis disease activity index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"3","key":"113_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/107602960300900301","volume":"9","author":"S Tsiara","year":"2003","unstructured":"Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost. 2003;9(3):177\u201390.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"113_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3109\/0886022X.2012.668741","volume":"34","author":"B Azab","year":"2012","unstructured":"Azab B, Daoud J, Naeem FB, et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients (3-year follow-up study). Ren Fail. 2012;34(5):571\u20136.","journal-title":"Ren Fail"},{"issue":"3","key":"113_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s11239-012-0718-6","volume":"34","author":"B Azab","year":"2012","unstructured":"Azab B, Shah N, Akerman M, McGinn JT. Value of platelet\/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34(3):326\u201334.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"113_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jcla.21564","volume":"27","author":"M Celikbilek","year":"2013","unstructured":"Celikbilek M, Dogan S, Ozbak\u0131r O, et al. Neutrophil\u2013 lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal. 2013;27(1):72\u20136.","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"113_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cytogfr.2006.04.003","volume":"17","author":"D Tousoulis","year":"2006","unstructured":"Tousoulis D, Antoniades C, Koumallos N, Stefanadis C. Pro- inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev. 2006;17(4):225\u201333.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"113_CR9","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s10753-013-9675-2","volume":"36","author":"A Ahsen","year":"2013","unstructured":"Ahsen A, Ulu MS, Yuksel S, et al. As a new inflammatory marker for familial Mediterranean fever: neutrophil-to- lymphocyte ratio. Inflammation. 2013;36(6):1357\u201362.","journal-title":"Inflammation."},{"issue":"10","key":"113_CR10","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/ijc.28536","volume":"134","author":"MX Li","year":"2014","unstructured":"Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134(10):2403\u201313.","journal-title":"Int J Cancer"},{"issue":"6","key":"113_CR11","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"113_CR12","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/rheumatology\/ker177","volume":"50","author":"M Macey","year":"2011","unstructured":"Macey M, Hagi-Pavli E, Stewart J, et al. Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behcet\u2019s disease. Rheumatology. 2011;50(10):1849\u201359.","journal-title":"Rheumatology."},{"issue":"14","key":"113_CR13","first-page":"3112","volume":"20","author":"Y Tulgar","year":"2016","unstructured":"Tulgar Y, Cakar S, Tulgar S, et al. The effect of smoking on neutrophil\/lymphocyte and platelet\/lymphocyte ratio and platelet indices: a retrospective study. Eur Rev Med Pharmacol Sci. 2016;20(14):3112\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"113_CR14","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/ard.2010.145995","volume":"70","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"113_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"SVD Linden","year":"1984","unstructured":"Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"113_CR16","first-page":"14","volume":"13","author":"K Abdul-Wahid","year":"2018","unstructured":"Abdul-Wahid K, Karhoot J, Al-Osami M, et al. Assessment of serum Calprotectin (S-100 protein) in Iraqi patients with Ankylosing spondylitis and its relation with treatment and disease activity. IOSR J Pharm Biol Sci. 2018;13(2):14\u20137.","journal-title":"IOSR J Pharm Biol Sci"},{"issue":"10089","key":"113_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384.","journal-title":"Lancet"},{"issue":"3","key":"113_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis inception cohort. Arthritis Rheum. 2009;60(3):717\u201327.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"113_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrrheum.2014.181","volume":"11","author":"A Van Tubergen","year":"2015","unstructured":"Van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nat Rev Rheumatol. 2015;11(2):110.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"113_CR20","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/art.38404","volume":"66","author":"J Bleil","year":"2014","unstructured":"Bleil J, Maier R, Hempfing A, et al. Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis. Arthritis Rheum. 2014;66(7):1745\u201354.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"113_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5606\/ArchRheumatol.2015.4837","volume":"30","author":"EE Inal","year":"2015","unstructured":"Inal EE, Sunar I, SARATA\u015e \u015e, et al. May neutrophil- lymphocyte and platelet-lymphocyte ratios indicate disease activity in ankylosing spondylitis? Arch Rheumatol. 2015;30(2):130\u20137.","journal-title":"Arch Rheumatol"},{"issue":"5","key":"113_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/jcla.21908","volume":"30","author":"R Mercan","year":"2016","unstructured":"Mercan R, Bitik B, Tufan A, et al. The association between neutrophil\/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal. 2016;30(5):597\u2013601.","journal-title":"J Clin Lab Anal"},{"issue":"1","key":"113_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5505\/abantmedj.2014.16878","volume":"3","author":"M \u00d6z\u015eahin","year":"2014","unstructured":"\u00d6z\u015eahin M, Demirin H, U\u00e7gun T, et al. Neutrophil-lymphocyte ratio in patients with ankylosing spondylitis. Abant Med J. 2014;3(1):16\u201320.","journal-title":"Abant Med J"},{"issue":"9","key":"113_CR24","first-page":"2912","volume":"7","author":"\u0130 Boyraz","year":"2014","unstructured":"Boyraz \u0130, Ko\u00e7 B, Boyac\u0131 A, et al. Ratio of neutrophil\/lymphocyte and platelet\/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF. Int J Clin Exp Med. 2014;7(9):2912\u20135.","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"113_CR25","first-page":"14","volume":"13","author":"I Boyraz","year":"2016","unstructured":"Boyraz I, Onur CS, Erdem F, et al. Assessment of relation between neutrophil lympocyte, platelet lympocyte ratios and epicardial fat thickness in patients with ankylosing spondylitis. Med Glas (Zenica). 2016;13(1):14\u20137.","journal-title":"Med Glas (Zenica)"},{"issue":"11","key":"113_CR26","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00405-016-3980-y","volume":"273","author":"N Bozan","year":"2016","unstructured":"Bozan N, Alpayc\u0131 M, Aslan M, et al. Mean platelet volume, red cell distribution width, platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients with ankylosing spondylitis and their relationships with high-frequency hearing thresholds. Eur Arch Otorhinolaryngol. 2016;273(11):3663\u201372.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"8","key":"113_CR27","first-page":"8570","volume":"9","author":"S Zhu","year":"2016","unstructured":"Zhu S, Cai M, Kong X, et al. Changes of neutrophil-to- lymphocyte ratio and red blood cell distribution width in ankylosing spondylitis. Int J Clin Exp Pathol. 2016;9(8):8570\u20134.","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"113_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5152\/eurjrheumatol.2014.034","volume":"1","author":"BN Co\u015ekun","year":"2014","unstructured":"Co\u015ekun BN, \u00d6ks\u00fcz MF, Ermurat S, et al. Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti-tumor necrosis factor (TNF) drugs for ankylosing spondylitis. Eur J Rheumatol. 2014;1(3):101\u20135.","journal-title":"Eur J Rheumatol"},{"issue":"4","key":"113_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/jcla.21768","volume":"29","author":"F G\u00f6kmen","year":"2015","unstructured":"G\u00f6kmen F, Akbal A, Re\u015eorlu H, et al. Neutrophil\u2013 lymphocyte ratio connected to treatment options and inflammation markers of Ankylosing spondylitis. J Clin Lab Anal. 2015;29(4):294\u20138.","journal-title":"J Clin Lab Anal"},{"issue":"12","key":"113_CR30","first-page":"722","volume":"116","author":"A Kucuk","year":"2015","unstructured":"Kucuk A, Uslu A, Ugan Y, et al. Neutrophil-to-lymphocyte ratio is involved in the severity of ankylosing spondylitis. Bratisl Lek Listy. 2015;116(12):722\u20135.","journal-title":"Bratisl Lek Listy"},{"issue":"7568","key":"113_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/bmj.38954.689583.DE","volume":"333","author":"CM McVeigh","year":"2006","unstructured":"McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ. 2006;333(7568):581\u20135.","journal-title":"BMJ."},{"issue":"6","key":"113_CR32","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ejim.2011.06.006","volume":"22","author":"A El Maghraoui","year":"2011","unstructured":"El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011;22(6):554\u201360.","journal-title":"Eur J Intern Med"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-0113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-020-0113-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-0113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:36:33Z","timestamp":1611794193000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-020-0113-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["113"],"URL":"https:\/\/doi.org\/10.1186\/s42358-020-0113-5","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"2 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the University of Baghdad, College of Medicine, Rheumatology and Medical Rehabilitation Unit in accordance with the Declaration of Helsinki with ethical approval reference no.: 2017070-EA-7189.Before becoming involved in the study, all participants who agreed to be involved in the study were given a cover letter describing the study objectives as well as a written informed consent form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}